Breaking News

MediLink Therapeutics, Roche Enter ADC Asset Alliance

Roche gains exclusive rights for the development, manufacturing, and commercialization of MediLink's ADC asset targeting solid tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MediLink Therapeutics has entered into a worldwide collaboration and license agreement with Roche for the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.   MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink’s ADC asset, YL211. MediLink will work with Roche’s R&D unit China Innovation Center of Roche (CI...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters